发展中国家药品专利保护与公共健康的冲突及平衡  

Conflict and Balance of Pharmaceutical Patent Protection and Public Health in Developing Countries

作　　者：殷莹[1] 董丽[1] 

机构地区：[1]沈阳药科大学工商管理学院,辽宁沈阳110016

出　　处：《中国药业》2015年第4期1-3,共3页China Pharmaceuticals

基　　金：2013年辽宁省创新药物孵化平台建设项目;项目编号:2013226027-14

摘　　要：公共健康危机引发了全球对专利保护合理性的探讨。在经济欠发达、公共保健措施不完善的发展中国家,大部分民众负担不起昂贵的药价,专利药的可及性低。药品专利制度下的高价专利药与发展中国家人民享有的健康权产生了矛盾。该文着眼于药品专利保护与发展中国家以合理价格获得药物这一冲突,分析了药品专利权与公共健康权的博弈,在《与贸易有关的知识产权协议》(TRIPS协议)框架下,为发展中国家达成更趋合理的药品专利与公共健康的平衡提出了建议。The public health crises have triggered the global discussions about the patent protection rationality. In the developing countries with the backward economy development and imperfect public health care measures,most of the people can not afford the expensive price of drugs,so the patented drugs have the lower acceptability. The contradiction between the high price of the patent drugs and the people＇s right to health in the developing countries is generated. This paper focuses on the conflict between the pharmaceutical patent protection and obtaining the medicines at a reasonable price in the developing countries,analyzes the game between pharmaceutical patent right and right to public health,finally proposes nine suggestions to achieve the balance between the pharmaceutical patent and the public health for the developing countries under the framework of Agreement on Trade- related Aspects of Intellectual Property Right（ TRIPS） agreement.

关 键 词：发展中国家 药品专利保护 公众健康 知识产权协议 

分 类 号：D923.4[政治法律—民商法学] R954[政治法律—法学]